Back to discover
Drug

gamma-Aminobutyric Acid

In clinical development
Actively researchedLate-stage developmentRising momentum
Also known as 4-aminobutanoic acid, 4-aminobutyric acid, 4Abu, AMINOBUTYRIC ACID+6 more

4-aminobutanoic acid, 4-aminobutyric acid, 4Abu, AMINOBUTYRIC ACID, GABA, GABA - gamma-aminobutyric acid, piperidic acid, piperidinic acid, .GAMMA.-AMINOBUTYRIC ACID, Gamma amino butyric acid.

31
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Sleep, Pain and Aging: Potential Underlying Mechanisms

Clinical trial2025-07-18Results posted · ClinicalTrials.gov

Neuronal network controlling REM sleep.

Research2024-07-07Journal of sleep research

Gephyrin promotes autonomous assembly and synaptic localization of GABAergic postsynaptic components without presynaptic GABA release.

Research2024-06-18Proceedings of the National Academy of Sciences of the United States of America

Effect of Gamma Aminobutyric Acid on ADHD and Seizures in Children With Epilepsy.

Clinical trial2019-10-30Results expected Q4 2028 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
gamma-Aminobutyric Acid
Aliases & brands
4-aminobutanoic acid4-aminobutyric acid4AbuAMINOBUTYRIC ACIDGABAGABA - gamma-aminobutyric acidpiperidic acidpiperidinic acid.GAMMA.-AMINOBUTYRIC ACIDGamma amino butyric acid
RxNorm CUI
4617
ChEMBL ID
CHEMBL96
ATC codes
N03AG03
UNII
2ACZ6IPC6I

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2025
1
Active studies
1
Recruiting
2
Late-stage (III+)
3
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 5
Phase 1 / 21Phase 22Phase 41Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Research activity

31 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19962025
Most influential

Synaptic modifications in cultured hippocampal neurons: dependence on spike timing, synaptic strength, and postsynaptic cell type.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1998 · 2,375 cites

GABAergic cell subtypes and their synaptic connections in rat frontal cortex.

Cerebral cortex (New York, N.Y. : 1991) · 1997 · 1,100 cites

Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1999 · 900 cites

Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014 · 831 cites

Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2002 · 592 cites

GABAergic cells are the major postsynaptic targets of mossy fibers in the rat hippocampus.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1998 · 592 cites
Major research themes8
gamma-Aminobutyric Acid8Astrocytes4Brain3Glutamic Acid3Neurotransmitter Agents3Receptors, GABA-A3Synapses3Alcoholism2
Journals, researchers & institutions
Top journals
  • The Journal of neuroscience : the official journal of the Society for Neuroscience8
  • Translational psychiatry2
  • Acta neuropathologica communications1
  • Acta pharmacologica Sinica1
  • Brain : a journal of neurology1
  • Brain and behavior1
Leading researchers
  • Freund TF2
  • Katona I2
  • Mackie K2
  • Sík A2
  • Acsady L1
  • Acsády L1
  • Akerman CJ1
  • Andersen JV1
Leading institutions
free-text, unnormalised
  • Imperial College London2
  • Institute of Experimental Medicine2
  • University of California2
  • Bio-Mimetic Control Research Center1
  • Brain Science Institute1
  • Center for Cognition and Sociality1

Related diseases

4 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 7 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

7 shared diseases1 shared paper

Studied across 3 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

3 shared diseases2 shared papers

Studied across 3 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as gamma-Aminobutyric Acid in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials